Clinical Trial Finder

Inclusion Criteria:

• - Body weight ≥ 40 kg.

• - Willing and able to provide signed written informed consent before any study-related screening procedures are performed.

• - Patients with histologically or cytologically confirmed diagnosis of advanced-stage or metastatic HER3+ solid tumors that are relapsed or refractory to or ineligible for standard therapy, or for whom no standard therapy is available; or the patient has documented their refusal of standard of care therapies.

These include the following: 1. Unresectable or metastatic cutaneous melanoma (HER3+) 2. Locally advanced or metastatic mutated EGFR (mEGFR) NSCLC (HER3+) 3. Unresectable, locally advanced or metastatic hormone receptor (HR)+/human epidermal growth factor receptor 2 (HER2)- breast cancer (HER3+)

• - If molecular pathology report to confirm HER3+ status is not available, willingness to undergo fresh tumor biopsy for assessment of HER3+ status.

• - Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2.

• - Contraceptive requirements: 1.

Women of childbearing potential (WOCBP) must use contraception from at least 28 days prior to study start, during the study, and for at least 6 months after the last dose of study drug. 2. Males who are sexually active with partner(s) who are WOCBP must agree to use a male condom with spermicide beginning at study start, during the study and for at least 6 months after the last dose of study drug.

• - Females must: 1.

Agree to not donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for at least 6 months after the last dose of study drug. 2. Agree to not breastfeed and do not plan to become pregnant during the study and for at least 6 months after the last dose of study drug.

• - Males must: 1.

Agree to not donate sperm beginning at study start, during the study, and for at least 6 months after the last dose of study drug. 2. Agree to not plan to father a child beginning at study start, during the study, and for at least 6 months after last dose of study drug.

• - Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

• - Any of the following treatment interventions within the specified time frame prior to study drug administration at study start: 1.

Any anti-tumor-directed drug therapy within 21 days or 5 times the elimination half-life (whichever is shorter). 2. Treatment with investigational drugs within 21 days. 3. Major surgery within 21 days. 4. Radiation therapy ≤4 weeks or radiotherapy that included >30% of the bone marrow. 5. Autologous or allogeneic stem cell transplantation or allogeneic tissue/organ transplant within 3 months. 6. CYP3A4 strong inhibitor (including any prescription or non-prescription drugs or herbal supplements) ≤4 half-lives. 7. CYP3A4 strong inducer ≤4 half-lives. 8. OATP1B inhibitor (including any prescription or non-prescription drugs or herbal supplements) ≤4 half-lives.

• - Prior treatment with a HER3-targeted ADC or any exatecan- or exatecan-derivative-conjugated ADC inhibitor as last line of therapy.

• - Prior treatment with a topoisomerase I inhibitor as last line of therapy.

• - Primary immune deficiency (e.g. congenital syndromes).

• - Active and uncontrolled infections requiring intravenous antibiotic or antiviral treatment within 2 weeks prior to study start.

• - Known/suspected hypersensitivity against ENV-501, human or humanized immunoglobulin Gs (IgGs), or their ingredients.

• - History of noninfectious or drug-induced pneumonitis or interstitial lung disease (ILD).

• - Known seropositivity (except after vaccination or confirmed cure for hepatitis) for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV).

• - Leptomeningeal disease, symptomatic or uncontrolled (active) brain metastasis (note: brain metastases not requiring steroids or anti-epileptic therapy are allowed if stable for ≥4 weeks prior to study start and patient is neurologically stable).

• - Pregnant or WOCBP who have a positive b-human chorionic gonadotropin (HCG) test result at Screening or within 7 days prior to study start.

• - Patients with second malignancies that are active (uncontrolled, metastatic) or requiring therapy.

• - Patient who is an immediate family member (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study site or the Sponsor.

Arms

Experimental: ENV-501

ENV-501 intravenous injection once every 3 weeks; successive cohorts will receive escalating doses of ENV-501 until the RP2D is reached

Interventions

Biological: - ENV-501

ENV-501 is a HER3-targeted antibody-drug conjugate (ADC) with a humanized monoclonal antibody (mAb) conjugated with a chemotherapeutic payload via a linker.